Psilocybin Shows Promise for OCD in New Research
A single dose of psilocybin may provide relief from obsessive compulsive disorder symptoms for weeks or even months.
Read More
Cleveland Clinic Study Validates Low Dose Ketamine for Chronic Pain
Cleveland Clinic has published the largest study to date examining low dose ketamine infusions for chronic refractory pain.
Read More
Bryan Johnson’s Psilocybin Longevity Experiment: Testing Psychedelics for Anti-Aging
Bryan Johnson, the biohacking entrepreneur known for his extreme anti-aging protocols, said he will test psilocybin as a longevity therapy.
Read More
Arizona Launches First Trial Using Whole Psilocybin Mushrooms for PTSD Treatment
Twenty four Arizonans living with post traumatic stress disorder will participate in a groundbreaking study next month.
Read More
FDA Program Promises to End Years of Ketamine Shortages for Mental Health Clinics
Phlow Corp. has been selected for the FDA's inaugural Commissioner's National Priority Voucher Pilot Program to manufacture ketamine's active pharmaceutical ingredient domestically.
Read More
October 2025 Roundup: What Ketamine Treatment Costs Across the United States
The cost of ketamine therapy continues to evolve. Here's what ketamine treatments cost across the US in October of 2025.
Read More
The Psychedelic Pharmaceutical Market Projected to Hit $17B in Next Decade
The global market for these compounds reached $4.75 billion in 2025. Analysts project growth to $16.93 billion by 2034.
Read More
A Breakthrough for Depression Treatment: FDA Fast Tracks atai’s Novel Nasal Spray
The FDA has granted Breakthrough Therapy designation to BPL-003, a nasal spray that could transform treatment for patients whose depression resists standard medications.
Read More
Federal Government Must Prepare for Psychedelic Medicine Expansion, VA Official Says
The statement signals a significant shift in how the government views mental health care for those who served.
Read More
Gavin Newsom Speeds Psychedelic Research With New Law Backed by Veterans
California Governor Gavin Newsom has signed Assembly Bill 1103, a measure to accelerate the study of psychedelics.
Read More